Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Cátedra de Clínica Médica de Pequeños Animales, U. de Endocrinología-Hospital Escuela de Medicina Veterinaria, Buenos Aires, Argentina; CONICET, Laboratorio de Endocrinología Molecular y Transducción de Señales, Instituto de Biología y Medicina Experimental, Buenos Aires, Argentina.
Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Cátedra de Clínica Médica de Pequeños Animales, U. de Endocrinología-Hospital Escuela de Medicina Veterinaria, Buenos Aires, Argentina.
Domest Anim Endocrinol. 2021 Jan;74:106578. doi: 10.1016/j.domaniend.2020.106578. Epub 2020 Oct 8.
Lipid disorders are relatively common in dogs. Hyperlipidemia can be primary or secondary to other diseases. In humans, fenofibrate is used to control hypertriglyceridemia. In dogs, there are no studies evaluating fenofibrate in hypertriglyceridemia. The aim of the study was to evaluate the safety and efficacy of fenofibrate to control severe hypertriglyceridemia in dogs. A total of 124 dogs (n = 124) with severe hypertriglyceridemia (>300 mg/dL, 3.39 mmol/L) were randomly distributed in the fenofibrate group (n = 64) and the diet group (n = 60). Dogs of the fenofibrate group were treated with fenofibrate (10 mg/Kg) once daily. Dogs of the diet group were treated with low-fat diet (10%). Serum triglycerides (TGs), total cholesterol (TC), liver enzymes, and creatine kinase concentrations were evaluated, before and after 1 mo of medical or dietary treatment. Triglyceride concentrations were reduced with fenofibrate (P < 0.001), and 85.93% of the dogs normalized their levels. Triglyceride concentrations also decreased with low-fat diet (P < 0.001), but only 26.6% of the dogs normalized their levels. Triglyceride concentrations were reduced with fenofibrate (P < 0.01) and with low-fat diet (P < 0.01). Of the cases with hypercholesterolemia, 53.7% and 50% of the dogs normalized their TC concentrations, with fenofibrate and diet, respectively. No significant adverse effects were observed (3% showed diarrhea). Fenofibrate was safe and effective in reducing and normalizing TG concentrations in dogs with severe hypertriglyceridemia, regardless of the cause of hyperlipidemia. The low-fat diet was effective in reducing, but not normalizing, TG concentrations. Fenofibrate and low-fat diet were effective in reducing TC concentrations. This is the first study evaluating fibrates in dogs with severe hypertriglyceridemia and comparing results with a low-fat diet.
脂质代谢紊乱在犬中较为常见。高脂血症可原发于其他疾病，也可继发于其他疾病。在人类中，非诺贝特被用于控制高甘油三酯血症。在犬中，尚无评估非诺贝特治疗高甘油三酯血症的研究。本研究旨在评估非诺贝特控制严重高甘油三酯血症犬的安全性和疗效。共 124 只（n = 124）严重高甘油三酯血症（>300mg/dL，3.39mmol/L）的犬随机分为非诺贝特组（n = 64）和饮食组（n = 60）。非诺贝特组犬给予非诺贝特（10mg/kg）每日 1 次；饮食组犬给予低脂饮食（10%）。在接受药物或饮食治疗 1 个月前后，评估血清甘油三酯（TGs）、总胆固醇（TC）、肝酶和肌酸激酶浓度。非诺贝特可降低 TG 浓度（P < 0.001），85.93%的犬 TG 水平恢复正常。低脂饮食也可降低 TG 浓度（P < 0.001），但只有 26.6%的犬 TG 水平恢复正常。非诺贝特和低脂饮食均可降低 TG 浓度（P < 0.01）。高胆固醇血症病例中，53.7%和 50%的犬分别用非诺贝特和饮食使 TC 浓度恢复正常。未观察到明显的不良反应（3%出现腹泻）。非诺贝特在降低和恢复严重高甘油三酯血症犬的 TG 浓度方面是安全有效的，而不论其高脂血症的病因。低脂饮食可有效降低 TG 浓度，但不能使其恢复正常。非诺贝特和低脂饮食可有效降低 TC 浓度。这是第一项评估严重高甘油三酯血症犬用非诺贝特治疗并与低脂饮食结果进行比较的研究。
